← 返回

基于 CRISPR 的肿瘤免疫治疗策略

英文原题:CRISPR-Based Approaches for Cancer Immunotherapy.

查看英文原题

CRISPR-Based Approaches for Cancer Immunotherapy.

PubMed 2023/01/01(内容时间) Crit Rev Oncog

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

成簇规律间隔短回文重复序列(CRISPR)技术是一种强大的基因编辑工具,有望彻底改变癌症治疗。它能够精准、高效地编辑驱动癌症生长和进展的特定基因。基于CRISPR的方法包括基因敲除,即删除癌细胞内的特定基因或DNA序列;以及基因敲入,即向癌细胞中插入新的DNA序列,以识别癌症治疗的潜在靶点。此外,全基因组CRISPR-Cas9筛选可识别癌症诊断的特定标志物。近年来,免疫治疗已成为高效的癌症治疗策略。CRISPR在癌症免疫治疗中的应用主要着眼于增强T细胞功能,使其更有效地攻击癌细胞,并使癌细胞的免疫逃逸机制失活。CRISPR还可用于生成CAR-T 细胞,即经基因工程改造、能够特异性靶向并攻击癌细胞的T细胞。本综述介绍CRISPR基因编辑策略及其组分在癌细胞中递送的最新进展,并讨论CRISPR在癌症免疫治疗中的应用。总体而言,本文有助于探索CRISPR策略在临床癌症免疫治疗中的潜力。

展开英文摘要原文

Clustered regularly interspaced short palindromic repeats (CRISPR) technology is a powerful gene editing tool that has the potential to revolutionize cancer treatment. It allows for precise and efficient editing of specific genes that drive cancer growth and progression. CRISPR-based approaches gene knock-out, which deletes specific genes or sequences of DNA within a cancer cell, and gene knock-in, which inserts new sequences of DNA into a cancer cell to identify potential targets for cancer therapy.

Further, genome-wide CRISPR-Cas9-based screens identify specific markers for diagnosis of cancers. Recently, immunotherapy has become a highly efficient strategy for the treatment of cancer. The use of CRISPR in cancer immunotherapy is focused on enhancing the function of T cells, making them more effective at attacking cancer cells and inactivating the immune evasion mechanisms of cancer cells.

It has the potential to generate CAR-T cells, which are T cells that have been genetically engineered to target and attack cancer cells specifically. This review uncovers the latest developments in CRISPR-based gene editing strategies and delivery of their components in cancer cells.

In addition, the applications of CRISPR in cancer immune therapy are discussed.

Overall, this review helps to explore the potential of CRISPR-based strategies in cancer immune therapy in clinical settings.

论文信息

作者
Malla RR、Middela K
第一作者单位
Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, School of Science, Gandhi Institute of Technology and Management (GITAM) (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India; Department of Biochemistry and Bioinformatics, School of Science, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India.India
通讯作者单位
Department of Biochemistry and Bioinformatics, School of Science, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India.India
文献类型
综述
期刊
Critical reviews in oncogenesis2023
原文标识
PubMed 38050977 · DOI 10.1615/CritRevOncog.2023048723